Loading...
Market
What will be the outcome of Brenus Pharma's Phase 1 clinical trials for its precision cancer vaccine by March 31, 2025?
2
Resolution / Starting Odds
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Official press release from Brenus Pharma or clinical trial registries
Story
Brenus Pharma Raises €22.2 Million ($25 Million) to Advance Cancer Vaccine Trials
Sep 19, 2024, 08:13 AM
Brenus Pharma, a French biotech company based in Lyon, has successfully raised €22.2 million ($25 million) in a Series A funding round. The funds will be used to accelerate the clinical trials of its precision cancer vaccines. The funding round was led by Angelor, a prominent investment firm. Brenus Pharma specializes in developing innovative cancer vaccines aimed at improving patient outcomes.
View original story
Similar markets
Yes • 50%
No • 50%
Successful • 33%
Partially Successful • 33%
Unsuccessful • 33%
Yes • 50%
No • 50%
Less than €10M • 25%
Between €10M and €20M • 25%
Between €20M and €30M • 25%
More than €30M • 25%
Successful with significant improvement in survival rates • 25%
Successful with moderate improvement in survival rates • 25%
No significant improvement in survival rates • 25%
Trial halted due to adverse effects • 25%
Increases by more than 10% • 25%
Increases by 0-10% • 25%
Decreases by 0-10% • 25%
Decreases by more than 10% • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Trial Resumed • 33%
Trial Terminated • 33%
Trial Modified • 34%
Significant Improvement • 33%
No Change • 33%
Significant Adverse Effects • 34%
Yes • 50%
No • 50%
Positive outcome with significant efficacy • 25%
Mixed outcome with limited efficacy • 25%
Negative outcome with no efficacy • 25%
Trial terminated early due to safety concerns • 25%
Significant tumor shrinkage • 25%
Improved survival rates • 25%
No significant effect • 25%
Other • 25%